A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Not yet recruiting 60 enrolled The First Affiliated Hospital of Zhengzhou University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of the combined treatment with Sacituzumab Tirumotecan in patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma.

Timeline

Start: 2025-09
Primary completion: 2028-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Sacituzumab Tirumotecan	Other / unclassified	5 mg/kg	Intravenous
Subject	Tislelizumab	Monoclonal antibody	200 mg	Intravenous

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

Summary

Timeline

Drugs

Indications